Por favor, use este identificador para citar o enlazar a este item:
Compartir / Impacto:
|Citado 92 veces en Web of Knowledge® | Ver citas en PubMed Central | Ver citas en Google académico|
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL|
|Exportar otros formatos:|
Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis
|Autor :||Ibáñez, Borja; Vilahur, Gemma; Cimmino, Giovanni; Speidl, Walter S.; Piñero, Antonio; Choi, Brian G.; Zafar, M. Urooj; Santos-Gallego, Carlos G.; Krause, Brian; Badimón, Lina; Fuster, Valentín; Badimón, Juan José|
|Palabras clave :||Apolipoprotein (apo) A-I(Milano)|
|Fecha de publicación :||18-mar-2008|
|Citación :||J Am Coll Cardiol. 51(11): 1104-1109 (2008).|
|Resumen:||[Objectives] This study sought to assess the effect of short-term apolipoprotein (apo) A-I(Milano) administration on plaque size and on suspected markers of plaque vulnerability.|
[Background] Long-term lipid-lowering interventions can regress and stabilize atherosclerotic plaques. However, the majority of recurrent events occur early after the first episode. Interventions able to acutely induce plaque regression and stabilization are lacking. Regression of human coronary lesions after 5 weeks of treatment with apoA-I(Milano) administration has been shown. However, there are no data regarding its effect on plaque vulnerability.
[Methods] Advanced aortic lesions were induced in New Zealand White rabbits (n = 40). Plaque size was assessed by magnetic resonance imaging (MRI) at the end of atherosclerosis induction. Animals were randomized to placebo or apoA-I(Milano) phospholipids (ETC-216), 2 infusions 4 days apart. After the last dose, another MRI study was performed and aortas were processed for cellular composition and gene protein expression of markers associated with plaque instability.
[Results] Pre-treatment MRI showed similar plaque size in both groups, whereas post-treatment MRI showed 6% smaller plaques in apoA-I(Milano)-treated animals compared with placebo (p = 0.026). The apoA-I(Milano) treatment induced a 5% plaque regression (p = 0.003 vs. pre-treatment), whereas the placebo showed no significant effect. Plaque regression by apoA-I(Milano) was associated with a reduction in plaque macrophage density and a significant down-regulation in gene and protein expression of tissue factor, monocyte chemoattractant protein-1, and cyclooxygenase-2, as well as marked decrease in gelatinolytic activity. Conversely, cyclooxygenase-1 was significantly up-regulated.
[Conclusions] Acute plaque regression observed after short-term apoA-I(Milano) administration was associated with a significant reduction in suspected makers of plaque vulnerability in an experimental model of atherosclerosis.
|Descripción :||PMID: 18342230|
A correction to this paper regarding a mistaken figure was published in: Journal of the American College of Cardiology, Volume 51, Issue 15, 15 April 2008, Page 1525.
|Versión del editor:||http://dx.doi.org/10.1016/j.jacc.2007.09.071|
|Aparece en las colecciones:||(CIC) Artículos|
Ficheros en este ítem:
No hay ficheros asociados a este ítem.